In response to the heated political rhetoric over the cost of prescription drugs, Novartis has decided not to raise prices on its medicines in the U.S. for the rest of 2018.
“When I looked at the policy environment in the U.S. with our team, we thought the prudent thing to do was to pull back on any further price increases in 2018 and evaluate as the environment evolves,” Novartis chief executive Vas Narasimhan told Bloomberg Television, shortly after the drug maker first disclosed its decision as part of its latest earnings report on Wednesday.
“Longer term our approach is to price our medicines base on the value they deliver,” he continued. “We’re going to look at price increases in line with the way medical inflation is happening overall.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
